Paris, France – 30 July 2020 – Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support financing of technology companies, has approved the eligibility of its Health for Life Capital II ™ fund as the first and only microbiome-focused fund.
As part of the initiative, French institutional investors have committed to devote over €5 billion to the financing of innovative companies by December 31, 2022. The objective is to help these innovative players to become regional, or even global organizations, while creating specific expertise for selected fields within the French ecosystem.
Seventure’s Health for Life Capital™ fund (HFL 2) is the world's co-leading and Europe’s leading investment fund specialising in the field of the microbiome, bringing together a team of 12 life science investors and eight operating experts in five European offices.
Continuing its successful “beyond the pill” investment strategy, HFL 2 primarily invests in areas related to the microbiota revolution, including platforms, drugs, nutritional solutions, diagnostics, and biomarkers. In addition, the fund also makes one-off investments in digital therapeutics, connected and digital health solutions, personalized nutrition, personalized medicine and foodtech.
The HFL funds invest in all stages (seed, venture, and significantly in growth capital), to date with around twenty innovative portfolio companies of an average ticket size of €15M, in one to three successive financing rounds. The funds target start-ups and more established innovative SMEs with a turnover of around €50M from all over the world, with particular focus on Europe, North America, Israel and Asia.
Seventure announced the first closing of HFL 2 at €100 million last year, while the final target of €200 million has already been exceeded. It is expected to close in November 2020 but is still open to professional investors until that date.
“Both HFL funds work with investors in all geographies, including family offices, prestigious industrial investors, such as Danone, Novartis, Lesaffre, Bel, as well as financial institutions, such as Bpifrance," said Isabelle de Crémoux, CEO and Managing Partner at Seventure Partners.
“Thanks to this strategy, we have seen over 1500 opportunities each year, ensuring a steady deal flow. We are delighted that the HFL 2 fund has already made five investments, including Axial, Galecto, Citryll and BCD.”
The HFL funds also allow co-investment with international financial and corporate players such as Novartis, Takeda, JNJ, Lundbeck, BMS, Nestlé, Kellogg’s, Tyson, Bunge and more with interest in the link between the microbiome, the food and health.
"The gut is home to a large number of bacteria, with 150 times more genes found here than the whole human genome. Everyone has a unique microbiome. Recent studies have shown the link between the alteration of the intestinal microbiome and metabolic pathologies, such as inflammatory bowel diseases (IBD), diabetes, obesity, Alzheimer's disease, Parkinson's disease, autism, depression, many cancers, cardiovascular, immune or autoimmune diseases - multiple sclerosis, asthma, food allergies, as well as other common and chronic pathologies. This is a field as fascinating as it is promising, constituting the medical revolution of the 21st century," she added.
Background on Seventure’s HFL funds
Since the launch of HFL I in 2014, Seventure Partners is today a recognized world leader in its field, a true pioneer of the microbiome revolution in the health and nutrition sectors. HFL has built an innovative international portfolio with investments in around twenty cutting-edge companies, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, LNC Therapeutics, TargEDys, A-mansia Biotech, BiomX, Microbiotica, Anaeropharma, LiMM Therapeutics , Siolta Therapeutics, Daytwo, Zipongo, Mdoloris Medical Systems, MycoTechnology or more. The first exit was made in 2017 with the sale of Cambrooke. HFL II will invest in a similar number of companies, with a global geography, but focus on Europe.
Legal note: The Health for Life Capital II™ investment vehicle is composed of a Luxembourg RAIF and a French FPCI (AIF). Seventure Partners acts as the AIF Manager of the RAIF, (Health for Life Management Sarl acting as General Partner), and as the Management Company of the FPCI. This Information is only intended for qualified investors (professional and well-informed investors). Health for Life Capital II™ bears a high risk. Investors could lose all of their investment.
About Seventure Partners and Health for Life Capital ™
With €750 million under management* as of December 31, 2018, Seventure Partners (Seventure) has been investing since 1997 in innovative companies with high growth potential, in two main areas: life sciences throughout Europe, Asia, Israel and North America, as well as digital technologies, primarily in France and Germany.Seventure invests both in more conventional approaches such as drugs, medical devices and diagnostics, industrial biotechnology, as well as applies its "beyond the pill" approach, including investing in related sectors such as digital and connected health, prevention, personalized medicine, nutrition and foodtech, with a particular interest in applications linked to the microbiome.
Seventure supports the development of companies from the seed or first rounds, to later rounds for financing technological development, with amounts invested between €500k and €10M per round of financing, and up to €20M per company.
In March 2018, Seventure launched AVF, a fund dedicated to animal food, nutrition and health, with Adisseo being a strategic partner for this fund.
Seventure launched HFL, the first fund to invest in life sciences (health, nutrition, digital / connected health) with a particular interest in the applications of microbiome-related discoveries in the health and human nutrition. This first fund of €160M, launched in 2014, invested in twenty leading companies in this field, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, BiomX, DayTwo, Zipongo, Microbiotica, A-Mansia, Cambrooke Therapeutics, Mdoloris Medical Systems, LNC Therapeutics, Targedys, MycoTechnology, LiMM Therapeutics, and more.
In January 2019, Seventure launched the second HFL II fund, with a target size of €200M, which has already been exceeded. This fund has already invested in Axial, Galecto, Citryll, BCD, and more.
These funds have attracted both financial investors, family offices, strategic manufacturers (Danone, Novartis, Tereos, Tornier, Lesaffre, Bel, Unigrains and other undisclosed multinational corporations), as well as entrepreneurs.
More information on the company: http://www.seventure.fr/en/. Follow us on Twitter @SeventureP and LinkedIn.
Issued for and on behalf of Seventure Partners by Instinctif Partners.
For more information please contact: firstname.lastname@example.org